3350 logo

Aadi Bioscience DB:3350 Stock Report

Last Price

€2.98

Market Cap

€71.1m

7D

35.5%

1Y

66.5%

Updated

25 Dec, 2024

Data

Company Financials +

3350 Stock Overview

A biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. More details

3350 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Aadi Bioscience, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Aadi Bioscience
Historical stock prices
Current Share PriceUS$2.98
52 Week HighUS$3.50
52 Week LowUS$1.18
Beta0.47
1 Month Change40.57%
3 Month Change81.71%
1 Year Change66.48%
3 Year Change-85.81%
5 Year Changen/a
Change since IPO-85.76%

Recent News & Updates

Recent updates

Shareholder Returns

3350DE BiotechsDE Market
7D35.5%-0.8%-1.6%
1Y66.5%-13.0%6.8%

Return vs Industry: 3350 exceeded the German Biotechs industry which returned -13.2% over the past year.

Return vs Market: 3350 exceeded the German Market which returned 6.8% over the past year.

Price Volatility

Is 3350's price volatile compared to industry and market?
3350 volatility
3350 Average Weekly Movement9.8%
Biotechs Industry Average Movement6.9%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 3350's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 3350's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
200753Dave Lennonaadibio.com

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway.

Aadi Bioscience, Inc. Fundamentals Summary

How do Aadi Bioscience's earnings and revenue compare to its market cap?
3350 fundamental statistics
Market cap€71.12m
Earnings (TTM)-€59.34m
Revenue (TTM)€24.11m

2.9x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3350 income statement (TTM)
RevenueUS$25.07m
Cost of RevenueUS$52.61m
Gross Profit-US$27.54m
Other ExpensesUS$34.15m
Earnings-US$61.69m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.50
Gross Margin-109.86%
Net Profit Margin-246.06%
Debt/Equity Ratio0%

How did 3350 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 04:32
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aadi Bioscience, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert BurnsH.C. Wainwright & Co.
Roger SongJefferies LLC
Boris PeakerTD Cowen